Press-release for stocks related to cancer for lly

tags : Cancer symbols : Lly

save search

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Published: 2024-04-02 (Crawled : 05:00) - prnewswire.com
LLY | News | $749.245 -0.2% 550K

Health Technology

| -3.34% | O: -2.79% H: 1.32% C: 1.18%
SNY | News | $45.445 -1.44% 2.6M

Health Technology

| -5.44% | O: -1.14% H: 0.02% C: -1.06%
review cancer treatment advanced china

Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 1.4K

Health Technology

| -7.26% | O: -0.26% H: 0.0% C: 0.0%
LLY | News | $749.245 -0.2% 550K

Health Technology

| -3.11% | O: 0.49% H: 0.84% C: -0.07%
SNY | News | $45.445 -1.44% 2.6M

Health Technology

| -6.28% | O: 1.06% H: 0.0% C: 0.0%
INCY | $52.46 -0.49% 330K

Health Technology

| -6.77% | O: -0.09% H: 1.42% C: 1.1%
ibi310 first cancer colon therapy study

Radiopharmaceuticals Market to Reach $11.6 Billion by 2034 as Cancer Treatment Gains Traction - Future Market Insights, Inc.
Published: 2024-03-25 (Crawled : 15:00) - prnewswire.com
NVSEF | News | $93.6375 6.88% 82K

Health Technology

| -2.86% | O: -100.0% H: NaN% C: Infinity%
NVS | News | $92.61 -0.51% 430K

Health Technology

| -3.27% | O: -0.08% H: 0.15% C: -0.44%
LLY | News | $749.245 -0.2% 550K

Health Technology

| -2.57% | O: 0.06% H: 0.96% C: 0.26%
CAH | $106.87 0.33% 220K

Distribution Services

| -3.46% | O: 0.02% H: 0.73% C: -0.02%
LNTH | $63.36 3.06% 620K

Health Technology

| 4.17% | O: 0.1% H: 1.98% C: -0.08%
reach cancer treatment market

Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-03-05 (Crawled : 22:00) - prnewswire.com
LLY | News | $749.245 -0.2% 550K

Health Technology

| -3.45% | O: 0.86% H: 0.45% C: -0.58%
association cancer research meeting

Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | $20.2 510

Health Technology

| -5.87% | O: 0.14% H: 0.0% C: -0.0%
SNYNF | News | $92.7 1.4K

Health Technology

| -3.13% | O: 0.26% H: 1.36% C: 1.36%
AZNCF | $140.15 560

Health Technology

| 6.54% | O: -0.85% H: 1.12% C: 0.43%
NVSEF | News | $93.6375 6.88% 82K

Health Technology

| -8.14% | O: 0.92% H: 0.0% C: 0.0%
UCBJY | $64.07 72K

Manufacturing

| 25.87% | O: 1.46% H: 0.44% C: 0.44%
ALPMY | News | $9.46 500K

Manufacturing

| -16.01% | O: -0.27% H: 0.0% C: -1.17%
TAK | $13.185 0.27% 570K

Health Technology

| -10.79% | O: -0.2% H: 0.14% C: -0.48%
NVS | News | $92.61 -0.51% 430K

Health Technology

| -9.24% | O: -0.06% H: 0.46% C: 0.29%
GSK | $39.44 -0.4% 560K

Health Technology

| -5.58% | O: -0.69% H: 1.42% C: 1.22%
LLY | News | $749.245 -0.2% 550K

Health Technology

| 0.65% | O: 2.37% H: 1.51% C: 0.79%
BMY | $48.145 0.64% 2.5M

Health Technology

| -5.21% | O: -0.65% H: 1.63% C: 1.48%
ABBV | $167.2 1.8% 1.3M

Health Technology

| -7.04% | O: -0.88% H: 1.46% C: 1.13%
SNY | News | $45.445 -1.44% 2.6M

Health Technology

| -2.16% | O: 1.67% H: 0.0% C: 0.0%
AZN | $68.635 0.15% 1.3M

Health Technology

| 4.88% | O: -2.81% H: 2.08% C: 1.38%
AMGN | $265.48 0.53% 360K

Health Technology

| -5.83% | O: -0.35% H: 1.15% C: 0.96%
lung reach cancer cell diagnostics therapy market

Blood Cancer Drugs Market Report 2023: Reveals Striking Growth Prospects with a Surge in R&D Activities - Long-term Forecasts to 2028 and 2033
Published: 2024-02-06 (Crawled : 00:00) - prnewswire.com
ALPMF | News | $9.594 2.2K

Health Technology

| -13.72% | O: -1.53% H: 0.0% C: 0.0%
AZNCF | $140.15 560

Health Technology

| 1.09% | O: -0.37% H: 0.0% C: 0.0%
NVSEF | News | $93.6375 6.88% 82K

Health Technology

| -8.98% | O: 0.41% H: 0.0% C: 0.0%
UCBJY | $64.07 72K

Manufacturing

| 37.02% | O: 1.71% H: 1.28% C: 0.94%
ALPMY | News | $9.46 500K

Manufacturing

| -14.23% | O: 0.28% H: 0.18% C: 0.0%
TAK | $13.185 0.27% 570K

Health Technology

| -7.13% | O: 0.07% H: 0.42% C: 0.07%
NVS | News | $92.61 -0.51% 430K

Health Technology

| -10.28% | O: 0.09% H: 0.39% C: -0.36%
JNJ | News | $144.86 0.06% 2.8M

Health Technology

| -7.04% | O: 1.47% H: 0.0% C: 0.0%
LLY | News | $749.245 -0.2% 550K

Health Technology

| 6.49% | O: 0.76% H: 4.31% C: 2.11%
BMY | $48.145 0.64% 2.5M

Health Technology

| -2.03% | O: -0.14% H: 0.35% C: -1.12%
ABBV | $167.2 1.8% 1.3M

Health Technology

| -4.15% | O: 1.48% H: 0.0% C: 0.0%
VRTX | $393.46 0.09% 350K

Health Technology

| -5.53% | O: 0.15% H: 2.4% C: 0.56%
SNY | News | $45.445 -1.44% 2.6M

Health Technology

| -0.9% | O: 1.33% H: 0.0% C: 0.0%
JAZZ | News | $107.995 0.84% 79K

Health Technology

| -14.12% | O: -0.02% H: 0.0% C: -1.4%
AZN | $68.635 0.15% 1.3M

Health Technology

| 1.83% | O: -0.4% H: 0.19% C: -0.33%
AMGN | $265.48 0.53% 360K

Health Technology

| -15.55% | O: -0.18% H: 0.0% C: -6.22%
report cancer blood growth market

Merck KGaA, Darmstadt, Germany, Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna
Published: 2024-01-04 (Crawled : 20:00) - biospace.com/
LLY | News | $749.245 -0.2% 550K

Health Technology

| 21.54% | O: 1.22% H: 1.78% C: -1.72%
merck cancer agreement

Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight
Published: 2023-12-20 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 1.4K

Health Technology

| -3.34% | O: -0.1% H: 0.0% C: 0.0%
JNJ | News | $144.86 0.06% 2.8M

Health Technology

| -7.46% | O: -1.87% H: 0.0% C: 0.0%
LLY | News | $749.245 -0.2% 550K

Health Technology

| 31.67% | O: 0.21% H: 0.63% C: 0.1%
SNY | News | $45.445 -1.44% 2.6M

Health Technology

| -5.45% | O: -0.08% H: 0.0% C: 0.0%
cancer growth study market

Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
Published: 2023-12-18 (Crawled : 12:30) - globenewswire.com
PNT | $13.68 2.63% 0.15% 0

| -9.84% | O: -10.09% H: 0.0% C: 0.0%
LLY | News | $749.245 -0.2% 550K

Health Technology

| 32.34% | O: 1.61% H: 1.14% C: 0.57%
LNTH | $63.36 3.06% 620K

Health Technology

| -19.15% | O: -19.87% H: 5.04% C: -8.75%
positive cancer biopharma topline trial results

Metastatic Prostate Cancer Market to Exhibit Positive Growth at a CAGR of 22% and 7.5% for mHSPC and mCRPC, respectively During the Study Period (2019-2032), Assesses DelveInsight
Published: 2023-12-13 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 1.4K

Health Technology

| -3.35% | O: 0.25% H: 0.0% C: 0.0%
LLY | News | $749.245 -0.2% 550K

Health Technology

| 28.73% | O: 1.8% H: 0.0% C: 0.0%
SNY | News | $45.445 -1.44% 2.6M

Health Technology

| -4.53% | O: 0.0% H: 0.0% C: 0.0%
positive cancer growth study market

Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life
Published: 2023-12-12 (Crawled : 22:00) - biospace.com/
LLY | News | $749.245 -0.2% 550K

Health Technology

| 25.42% | O: -2.88% H: 0.0% C: 0.0%
LGND | News | $74.86 -5.08% 36K

Health Technology

| 26.11% | O: 0.21% H: 1.18% C: 0.43%
breast life cancer pharmaceuticals results

Metastatic Castration-Sensitive Prostate Cancer Market to Skyrocket at Astounding 22% CAGR During the Study Period (2019-2032), assesses DelveInsight
Published: 2023-12-06 (Crawled : 22:00) - prnewswire.com
LLY | News | $749.245 -0.2% 550K

Health Technology

| 27.54% | O: -0.35% H: 0.0% C: 0.0%
cancer study market

Metastatic Non-small Cell Lung Cancer Market Forecast Analysis and with Focus on its Immune/Molecular Biomarker Types: PD-L1, EGFR, KRAS, ALK, BRAF, MET, ROS-1, HER2, RET fusion, and NTRK1/2/3 Gene fusion | DelveInsight
Published: 2023-11-28 (Crawled : 22:00) - prnewswire.com
JNJ | News | $144.86 0.06% 2.8M

Health Technology

| -4.39% | O: -0.04% H: 0.0% C: 0.0%
LLY | News | $749.245 -0.2% 550K

Health Technology

| 26.85% | O: -0.06% H: 0.0% C: 0.0%
SNY | News | $45.445 -1.44% 2.6M

Health Technology

| -1.85% | O: -0.15% H: 0.07% C: -0.66%
BPMC | $89.93 1.75% 94K

Health Technology

| 25.92% | O: 0.5% H: 1.86% C: -0.33%
lung biomarker cancer cell market

Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium
Published: 2023-11-28 (Crawled : 15:30) - biospace.com/
LLY | News | $749.245 -0.2% 550K

Health Technology

| 26.92% | O: 0.05% H: 0.0% C: 0.0%
LGND | News | $74.86 -5.08% 36K

Health Technology

| 33.66% | O: 0.49% H: 0.83% C: -2.14%
breast symposium presentation cancer pharmaceuticals

SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
Published: 2023-10-26 (Crawled : 13:00) - globenewswire.com
LLY | News | $749.245 -0.2% 550K

Health Technology

| 28.02% | O: -1.68% H: 0.0% C: 0.0%
BYSI | $1.8 -2.7% 21K

Health Technology

| 60.71% | O: 0.0% H: 7.14% C: -5.36%
candidate symposium cancer protein therapeutics molecular

Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023
Published: 2023-10-21 (Crawled : 16:20) - prnewswire.com
LLY | News | $749.245 -0.2% 550K

Health Technology

| Email alert Add to watchlist
retevmo lung congress symposium cancer cell thyroid results

Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer
Published: 2023-10-20 (Crawled : 12:00) - prnewswire.com
LLY | News | $749.245 -0.2% 550K

Health Technology

| 25.11% | O: -1.52% H: 0.0% C: 0.0%
verzenio breast cancer impact

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
Published: 2023-10-13 (Crawled : 13:00) - prnewswire.com
PYXS | $4.75 -1.66% 100K

Professional, Scientific, and T...

| 147.69% | O: 0.0% H: 2.56% C: 2.56%
LLY | News | $749.245 -0.2% 550K

Health Technology

| 23.38% | O: 1.15% H: 0.0% C: 0.0%
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -40.22% | O: -1.63% H: 4.97% C: 2.76%
MRUS | $40.5 -1.34% 99K

Health Technology

| 94.73% | O: 0.47% H: 1.7% C: -0.38%
AZN | $68.635 0.15% 1.3M

Health Technology

| 0.23% | O: -0.59% H: 0.62% C: -0.56%
fda year review cancer pancreatic

Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period (2019-2032), Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo
Published: 2023-10-04 (Crawled : 21:00) - prnewswire.com
LLY | News | $749.245 -0.2% 550K

Health Technology

| 43.21% | O: 1.72% H: 0.0% C: 0.0%
RVMD S | $36.9 0.22% 250K

Health Technology

| 51.27% | O: -0.58% H: 4.83% C: 4.38%
IOVA M | $11.8 1M

Health Technology

| 188.51% | O: 0.24% H: 3.66% C: 1.95%
BNTX | $86.085 -0.37% 160K

Health Technology

| -21.68% | O: -0.44% H: 1.52% C: 0.08%
AXSM | $68.855 -1.23% 110K

Health Technology

| 6.5% | O: -0.43% H: 4.97% C: 4.71%
lung companies cancer study market

Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Published: 2023-10-04 (Crawled : 16:00) - prnewswire.com
LLY | News | $749.245 -0.2% 550K

Health Technology

| 39.79% | O: -2.39% H: 0.0% C: 0.0%
conference cancer international therapeutics molecular

← Previous
1
2
3
4
5
6
7
Next →

tags : Cancer symbols : Lly

save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

tags : Cancer symbols : Lly save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

tags : Cancer symbols : Lly

save search